After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, YMAB falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Y-Mabs Therapeutics Inc is $386.68M. A total of 1.31 million shares were traded on the day, compared to an average of 661.80K shares.
In the most recent transaction, Rossi Michael J sold 3,917 shares of YMAB for 5.20 per share on Mar 07 ’25. After the transaction, the PRESIDENT & CEO now owns 137,083 company shares. In a previous transaction on Mar 07 ’25, Gad Thomas sold 10,810 shares at 5.23 per share. YMAB shares that CHIEF BUSINESS OFFICER owns now total 202,721.
Among the insiders who bought shares, Rajah Vignesh acquired of 4,946 shares on Mar 07 ’25 at a per-share price of $5.20. In another insider transaction, Smith Susan Laura bought 5,528 shares at $5.26 per share on Mar 07 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, YMAB has a high of $16.11 and a low of $3.55.
As of this writing, YMAB has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.12 per share and a lower estimate of -$0.3. The company reported an EPS of -$0.16 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. YMAB’s latest balance sheet shows that the firm has $181.56M in Cash & Short Term Investments as of fiscal 2021. There were $3.63M in debt and $27.88M in liabilities at the time. Its Book Value Per Share was $1.93, while its Total Shareholder’s Equity was $180.11M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for YMAB is Buy with a score of 2.90.
